CRYSVITA for tumor-induced osteomalacia (TIO)
CRYSVITA targets FGF23, the underlying cause of chronic hypophosphatemia in patients with TIO1
CRYSVITA is the first and only FDA-approved therapy for the treatment of FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.1
CRYSVITA was evaluated in two Phase 2 clinical trials of 27 adults with TIO for:
- Changes in serum phosphorus levels
- Healing of osteomalacia, as assessed by bone histomorphometry
FGF23, fibroblast growth factor 23.